Acuril

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acuril

What is Acuril?

Acuril is a pharmaceutical medication developed for the management of specific conditions affecting the lower urinary tract. It belongs to a class of drugs designed to address symptoms associated with bladder dysfunction and related neurological or muscular imbalances in the pelvic region.

Mechanism of Action

The active components in Acuril work by interacting with specific receptors in the bladder wall and the surrounding smooth muscle tissue. By modulating these pathways, the medication helps to regulate the signaling process between the nervous system and the bladder. This action is intended to stabilize muscle activity, which can assist in maintaining more consistent bladder control and reducing involuntary contractions.

Therapeutic Intent

Acuril is primarily utilized to improve the quality of life for individuals experiencing chronic urinary symptoms. It is often prescribed when non-pharmacological interventions, such as behavioral therapies or physical exercises, have not provided sufficient relief. The medication aims to provide symptomatic support by:

  • Reducing the frequency of the urge to urinate.
  • Increasing the functional capacity of the bladder.
  • Alleviating discomfort associated with bladder overactivity.

Form and Administration

Acuril is typically produced as an oral tablet or capsule. It is designed for systemic absorption, allowing the active ingredients to reach the targeted physiological sites through the bloodstream. The formulation may vary in strength to accommodate different patient profiles and the severity of the underlying condition.

Regulatory References

  1. Angiotensin-Converting Enzyme Inhibitors (ACEI) - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Acuril?

Acuril (Ramipril) safety information is strictly derived from regulatory documents, classifying possible adverse reactions by frequency and the body system affected.

Official Adverse Reactions and System-Organ Classes

The most Common adverse reactions, defined as occurring in 1% to 10% of patients in official data, include a persistent, non-productive cough, headache, fatigue, and dizziness. Effects related to the vascular system, such as hypotension (low blood pressure), are also frequently documented.

Classification Example Adverse Reaction (System-Organ Class)
Common Persistent Cough (Respiratory System)
Common Dizziness, Headache (Nervous System)
Uncommon Renal function impairment (Renal System)

Serious Adverse Reactions and Safety Constraints

Certain severe adverse reactions are explicitly documented in regulatory labeling. Angioedema, which involves rapid and potentially life-threatening swelling of the face, lips, tongue, or throat, is a rare but critical risk associated with ACE inhibitors. Cases of Hepatotoxicity (severe liver injury) have also been reported.

Safety is often tied to patient characteristics and timing. The medication is formally Contraindicated in specific conditions, including during the second and third trimesters of Pregnancy due to confirmed fetal risk, and in patients with a history of ACE inhibitor-induced Angioedema.

Additionally, official documents note that effects such as excessive hypotension are more likely to occur at the initiation of treatment or during dose increases. The safety profile recommends routine monitoring of key parameters, such as serum potassium and renal function (creatinine), to manage known risks like hyperkalemia and acute kidney injury.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Acuril overdose centers on its significant impact on the circulatory system and subsequent physiological stability, necessitating immediate emergency action. The most prominent risk is the potential for profound hemodynamic instability.

Documented Overdose Manifestations

Overdose is primarily characterized by Severe Hypotension (a profound drop in blood pressure) and Bradycardia (abnormally slow heart rate). These events may lead to secondary symptoms such as lightheadedness, dizziness, and syncope (fainting), which are attributable to insufficient blood flow. Severe outcomes documented in regulatory information include the risk of Cardiovascular Shock and potential Acute Renal Failure. Furthermore, an overdose can result in the metabolic finding of Hyperkalemia (elevated serum potassium levels). Population-specific notes indicate that Hypoglycemia (low blood sugar) is a specific concern reported in pediatric overdose cases.

Emergency Actions and Required Monitoring

Action/Status Regulatory Guidance on Management and Response
Urgent Help Required Seek immediate medical attention for any suspected overdose. Contact emergency services immediately if the individual experiences fainting, signs of shock, or difficulty breathing.
Management Status No widely available specific antidote is established; care is focused on supportive measures. Treatment prioritizes volume expansion via saline infusion to correct hypotension.
Monitoring Asymptomatic patients require observation for a minimum of 6 hours. Symptomatic or hypotensive individuals require hospital monitoring for at least 24 hours to stabilize vital signs and metabolic status, including monitoring for Hyperkalemia.

Therapeutic Uses of Acuril

What Acuril Treats: Main Uses and Benefits

This medication is applied across domains where additional symptomatic support is needed, primarily to address symptoms related to physical discomfort and systemic imbalance. It is used to help with elevated body temperature and to provide temporary relief of pain. It is relevant in clinical settings that involve acute or unstable symptom patterns, such as managing general aches, headaches, muscle pain, and fever associated with the common cold or flu-like illnesses. The supportive relief is relevant for managing symptoms that interfere with daily functioning and create noticeable physiological strain.

“It is applied in scenarios where additional management of discomfort is required to help patients cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Pain and Fever This medication is relevant in conditions characterized by periods of heightened symptoms where functional stability becomes affected, and is commonly used when symptoms intensify and supportive relief is needed. It provides support that helps ease the overall symptom burden, assisting with maintaining comfort and contributing to easing the overall symptom load during symptomatic phases.

Regulatory References

  1. Canada.ca (Health Canada) guidance

Eligibility and Restrictions for Use

Acuril (quinapril) use is strictly governed by official regulatory criteria that define the eligible patient population and those for whom the drug is strictly prohibited or requires special consideration.

Populations for Whom Use is Prohibited (Contraindications)

Official documents prohibit the use of Acuril in the following populations:

  • History of Angioedema: Patients with a history of angioedema (swelling of the face, lips, tongue, or throat) related to previous treatment with any Angiotensin-Converting Enzyme (ACE) inhibitor, or patients with hereditary/idiopathic angioedema.
  • Pregnancy: The drug is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury and death. Discontinuation is mandatory as soon as pregnancy is detected.
  • Concomitant Drug Use: Patients receiving a Neprilysin inhibitor (e.g., sacubitril) must not use Acuril within 36 hours of the last dose. It is also contraindicated for use with Aliskiren in patients with diabetes.

Other Eligibility Considerations

  • Pediatric Use: Safety and effectiveness for pediatric patients (children) have not been established.
  • Organ Impairment: Use in patients with significant renal or hepatic impairment requires special caution and may necessitate dose adjustments as determined by a healthcare provider.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents structure the interaction profile of Acuril (Ramipril) around pharmacodynamic effects and the risk of severe systemic outcomes.

Documented Interaction Restrictions

Interaction Type Interacting Substance/Class Official Constraint/Outcome
Contraindicated Combination Sacubitril/Valsartan (Neprilysin Inhibitor) Prohibited due to severe angioedema risk. Requires a mandatory 36-hour separation period between last dose.
Contraindicated Combination Aliskiren (Direct Renin Inhibitor) Prohibited in patients with diabetes mellitus.
Pharmacodynamic Risk Potassium-sparing Diuretics or Potassium Supplements Increased risk of Hyperkalemia (elevated serum potassium levels).
Pharmacodynamic Risk Diuretics or Alcohol (Ethanol) Risk of Excessive Hypotension (additive effects in lowering blood pressure).
Exposure Modification Lithium Reduces Lithium’s renal clearance, leading to increased serum levels and potential toxicity.
Pharmacodynamic Risk NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) May reduce antihypertensive effect and increase the risk of renal function deterioration, especially in the elderly.

The profile highlights that combining Ramipril with agents affecting the Renin-Angiotensin-Aldosterone System (RAAS) carries an increased risk of severe adverse outcomes. The documented interaction with food decreases the rate of absorption without affecting the total systemic exposure.

Mechanism of Action

The mechanism involves Ramiprilat, the active metabolite of the prodrug Ramipril, modulating systems that influence vascular tension and fluid balance. The drug's central action is the competitive inhibition of the Angiotensin-Converting Enzyme (ACE). By blocking this enzyme, Ramiprilat immediately suppresses the formation of Angiotensin II, a key signaling molecule within the Renin-Angiotensin-Aldosterone System (RAAS). This initiates a cascade that alters the homeostatic regulation of vascular resistance.

ACE is functionally identical to Kininase II, meaning its inhibition simultaneously prevents the breakdown of the vasodilator peptide Bradykinin (from the Kallikrein-Kinin System). This dual action—reduced Angiotensin II and increased Bradykinin—results in arterial vasodilation (widening of arteries). The downstream suppression of Aldosterone results in increased excretion of salt and water (natriuresis and diuresis), which modulates the circulating fluid volume. Beyond immediate effects, the sustained reduction of Angiotensin II interrupts molecular signals that promote growth factors. This anti-remodeling effect occurs by limiting the Angiotensin II-mediated development of hypertrophy and fibrosis in myocardial and vascular tissues.

Dosage and Administration Information

Instruction Map: How to Use Acuril — Administration Overview

Acuril is provided in capsules or tablets for oral administration and is used according to a structured regimen that requires gradual dose adjustment, known as titration. Its standard dosage forms include strengths such as 1.25 mg, 2.5 mg, 5 mg, and 10 mg.

Dosage and Frequency Patterns

For managing hypertension, therapy typically initiates with a dose of 2.5 mg once daily, although a 1.25 mg dose is used for patients concurrently taking diuretics or those with a strongly activated Renin-Angiotensin System. The dose is not fixed but is titrated upward over intervals of 2 to 4 weeks, with a daily maximum of 20 mg for hypertension. For long-term cardiovascular risk reduction, the target dose is 10 mg once daily. In post-myocardial infarction heart failure, the target is often 5 mg twice daily, totaling 10 mg per day. The frequency is usually once daily, but some regimens, such as for heart failure, require twice-daily divided dosing.

Specific Administration Instructions

Acuril can be taken with or without food, as the medicine’s absorption is not significantly affected by meals. The capsule or tablet is intended to be swallowed whole and is not to be chewed or crushed. If the capsule cannot be swallowed, the contents can be mixed with 4 oz (120 mL) of water, apple juice, or applesauce; this entire mixture is to be consumed immediately or within 24–48 hours depending on storage conditions.

Population-Specific Adjustments

Specific dose adjustments are applied for patients with reduced organ function. For those with confirmed renal impairment (creatinine clearance 40 mL/min or less), the initial dose is reduced to 1.25 mg once daily, and the maximum dose is limited to 5 mg per day. Patients with hepatic impairment should not exceed 2.5 mg daily, and treatment is initiated under close medical supervision.

Recent Clinical Evidence

Research evidence / Overview of studies for Acuril

Acuril has been the subject of several clinical investigations, including Randomized Controlled Trials (RCTs) and systematic reviews, which are common methods for evaluating medicines. These studies primarily explore how Acuril is associated with certain cardiovascular and kidney-related measured endpoints in specific patient populations.


Evidence for use in Managing High Blood Pressure (Hypertension)

Research has widely examined the use of Acuril in adult patients diagnosed with high blood pressure, using short- and intermediate-term RCTs and analyses of existing data. Studies monitored a measured endpoint: the change in systolic and diastolic blood pressure (BP) readings over defined time intervals. Findings describe patterns observed in these studies, where patterns of change in recorded BP readings were measured in the observed adult populations.

Specific long-term data focusing solely on blood pressure maintenance are less characterized, as data for this measured endpoint are often integrated into trials that also track major cardiovascular events.


Evidence for Preventing Major Cardiovascular Events in High-Risk Patients

Research has included large, multi-year, placebo-controlled Randomized Controlled Trials involving adults considered high risk, such as those with pre-existing vascular disease or diabetes alongside other risk factors. The primary measured endpoint was the occurrence of a composite event, tracking recorded instances of heart attack, stroke, or cardiovascular-related mortality.

Studies documented a pattern where the incidence of the measured major cardiovascular composite endpoint was tracked in the group receiving Acuril compared to the placebo group over the typical 4.5 to 5-year follow-up period. The results apply only to the populations studied, and certainty remains low regarding whether the observed findings are identical across all ethnic and global patient subgroups.


Evidence Related to Chronic Kidney Conditions (Nephropathy)

Studies monitored measured endpoints related to functional imbalance in the kidneys of patients with diabetes mellitus, primarily by tracking the amount of protein in the urine (albuminuria) and monitoring the rate of progression to more severe stages of kidney damage. Research highlights changes measured during the study period, documenting patterns where the measured protein excretion was tracked in the urine of diabetic patients. Comparative evidence is lacking for patients with non-diabetic kidney disease.

Key Studies & References

  1. Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure (AIRE 2021 follow-up)

Frequently Asked Questions (FAQ)

Common questions about Acuril (FAQ)


Q: Does Acuril require any special blood tests while taking it?

Regulatory documents recommend the routine monitoring of certain laboratory values while taking Acuril. This may involve blood tests to check values, such as serum potassium and to assess renal function (kidney function), which aligns with the routine monitoring recommended for managing known risks associated with this class of medication.


Q: Does Acuril have a 'Black Box Warning' in official drug materials?

Yes. Official regulatory documents include a Boxed Warning, which is the strongest safety warning, concerning the risk of fetal injury and death. This warning applies specifically if Acuril is used during the second or third trimesters of pregnancy.


Q: Is Acuril known to interact with birth control pills?

Official documents that detail known and tested drug interactions for Acuril do not specifically list oral contraceptive medications, such as birth control pills, as an interacting substance. As with any medicine, it is standard practice to discuss all medications with a healthcare provider.


Q: Is it common for people to feel slightly tired after taking Acuril?

Fatigue is documented in official sources. Official safety data classifies fatigue—a general feeling of tiredness or weakness—as a common adverse reaction, which means it is documented to occur in 1% to 10% of patients in clinical studies.


Q: How quickly do people typically expect Acuril to start working?

Studies indicate that after taking a single dose of Acuril, the lowering of blood pressure may be observed within one to two hours. The maximum blood pressure reduction is typically achieved three to six hours after administration.


Q: How long does one dose of Acuril stay active in the body?

Clinical studies suggest that the effect of a single dose on blood pressure generally lasts for 24 hours. The active substance is slowly cleared from the body over an extended period, influencing systemic functions.


Q: Are there any common interactions between Acuril and cold medicines?

Regulatory documents indicate caution when combining Acuril with certain types of medicines often found in cold and flu products (e.g., sympathomimetics), as official sources suggest this combination may risk excessive lowering of blood pressure (hypotension).


Q: What distinguishes Acuril from other medicines used for similar conditions?

Acuril (Ramipril) belongs to the ACE inhibitor class, which works by blocking a key enzyme involved in blood pressure regulation. Differences between medicines in this class generally relate to their chemical structure, potency, and especially their duration of action or required dosing frequency.


Q: Are there any food types that are known to interact with Acuril?

Official product information advises caution regarding dietary intake of potassium. Acuril may increase potassium levels in the blood. For this reason, official safety information highlights the importance of avoiding moderately high or high potassium intake, including salt substitutes containing potassium.


Q: What happens if a person misses a dose of Acuril?

Regulatory patient information states that if a dose is missed, it is typically taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. Patients are cautioned not to take a double dose to compensate for the missed one.


Q: Is Acuril considered a long-term medication?

For its approved uses, such as managing hypertension and reducing long-term cardiovascular risk, treatment with Acuril is often described in regulatory documents as long-term and may be continued indefinitely based on individual health status.


Q: What is the research evidence basis for Acuril's approval?

Regulatory approval is based on extensive clinical evidence, including large, multi-year, placebo-controlled Randomized Controlled Trials (RCTs). These studies examine measured endpoints like changes in blood pressure and the incidence of major cardiovascular events.


Q: Do studies suggest Acuril has different effects on men versus women?

Sub-analyses of clinical studies, such as those examining major cardiovascular endpoints, have noted that a similar beneficial effect was generally observed in both male and female patients studied across those outcomes.


Q: Is Acuril often prescribed for uses other than its main indication?

Acuril is officially indicated for multiple uses approved by regulatory bodies, including treating hypertension (high blood pressure), managing heart failure, and reducing overall cardiovascular risk in high-risk patients.


Q: What should be done if someone accidentally takes too much Acuril?

Regulatory patient information describes the procedure for overdose, which includes immediately contacting poison control services or local emergency services (such as 911).


Q: Are the initial side effects of Acuril temporary or do they often last?

Official documents note that some effects, such as excessive hypotension (low blood pressure), are more commonly observed when treatment is initiated or the dose is increased. The non-productive cough, a common side effect, is known to resolve after the medicine is discontinued.


Q: What are the typical non-serious side effects associated with Acuril?

The most frequently documented adverse reactions, classified as common (occurring in 1% to 10% of patients), include a persistent cough, headache, and general feelings of dizziness or tiredness.


Q: Is there a certain time of day that Acuril is typically recommended to be taken?

Regulatory documents state that Acuril is generally taken once or twice a day and can be taken with or without food. There is no specific time of day (morning or evening) that is strictly mandated in the official administration instructions.


Q: Are there any specific organs Acuril is known to affect over time?

Acuril is a cardiovascular medicine intended to support the heart and blood vessels. However, due to its mechanism of action, official safety information requires the monitoring of both renal (kidney) function and liver function during treatment.


Q: How reliable is the scientific research backing Acuril?

The evidence supporting the officially approved uses of Acuril relies on established scientific standards. This includes large-scale, controlled studies, such as Randomized Controlled Trials, which are standard evaluation methods for cardiovascular medicines.


Q: Is Acuril sometimes used as a preventative medicine?

One of the official labeled uses for Acuril is the reduction of cardiovascular risk, which acts as a preventative measure against events such as heart attack, stroke, and cardiovascular death in patients considered to be at high risk.


Q: How long after stopping Acuril are its effects completely gone?

Regulatory documents specify a required 36-hour separation period (washout) between the last dose of Acuril and the start of certain other cardiovascular medicines (Neprilysin inhibitors) to prevent a serious interaction risk. This is the official safety-related clearance timeframe.


Q: Are there any common interactions between Acuril and vitamin D supplements?

Official drug interaction databases used in medical references do not list a specific interaction between Acuril and Vitamin D supplements. It is important that a healthcare professional is informed about the full supplement regimen.


Q: Do people with asthma need to be cautious about using Acuril?

Official regulatory documents detailing contraindications and specific cautions for Acuril do not list asthma as a prohibited condition or a specific high-risk factor that must be addressed before use.

How should Acuril be stored and disposed of?

Storage Requirements

Acuril (ramipril) must be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, which should be tightly closed, and stored away from excess heat, moisture, and light. The official labeling mandates that the medicine must be kept out of the reach of children to prevent accidental exposure.

Handling/Protection Requirement
Temperature Store at controlled room temperature (20 C–25 C).
Environment Protect from moisture, excessive heat, and light; Do not freeze.
Container Keep in original, tightly closed container.
Stability Mixture of capsule contents and liquid/food is stable for 24 hours at room temperature or 48 hours refrigerated.

Disposal Instructions

Official guidelines recommend using a drug take-back program or authorized collection site as the best method for disposing of unused or expired Acuril. Since ramipril is not on the FDA's flush list, it should not be flushed down the toilet. If a take-back program is unavailable, the medicine should be mixed with an undesirable substance (like coffee grounds), sealed in a plastic bag, and then discarded in the household trash. All personal information should be removed from the container before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acuril found in:

A-Z Index: